Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model

Osteoporosis International

Volumn 26, Issue 5, 2015, Pages 1477-1489

  Si, L ^a,b   Winzenberg, T M ^a,c   Jiang, Q ^b   Palmer, A J ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Cost utility analysis; Cost effectiveness analysis; Model; Osteoporosis

Indexed keywords

BONE DENSITY CONSERVATION AGENT;

AGE DISTRIBUTION; AGED; CHINA; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PREVALENCE; PROBABILITY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VALIDATION STUDY; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CHINA; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMETRIC; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PREVALENCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84939968885     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2999-4     Document Type: Article

References (77)

1. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276–1287
2. Mithal A, Ebeling P, Kyer CS (2013) Asia-pacific regional audit: epidemiology, costs & burden of osteoporosis in 2013. International Osteoporosis Foundation, Nyon
3. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch osteoporos 8:136
4. Watts JJ, Abimanyi-Ochom J, Sanders KM (2013) Osteoporosis costing all Australians: a new burden of disease analysis—2012 to 2022. Osteoporosis Australia
5. Torrance GW, Drummond MF (2005) Methods for the economic evaluation of health care programmes. Oxford university press
6. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394–401
7. Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK (2006) Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 26:194–206
8. Mueller D, Weyler E, Gandjour A (2008) Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 26:513–536
9. Nayak S, Roberts MS, Greenspan SL (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 155:751–761
10. Si L, Winzenberg TM, Palmer AJ (2014) A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 25:51–60
11. Kanis JA, Hiligsmann M (2014) The application of health technology assessment in osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism
12. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146
13. Kingkaew P, Maleewong U, Ngarmukos C, Teerawattananon Y (2012) Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis. Value Health 15:S20–S28
14. NICE (2012) Osteoporosis: assessing the risk of fragility fracture. NICE clinical guideline. National Clinical Guideline Centre, Manchester
15. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB (2012) Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making 32:733–743
16. China Center for Health Economic Research (2011) China Guidelines for Pharmacoeconomic Evaluations. Beijing
17. Magee DJ, Zachazewski JE, Quillen WS (2007) Scientific foundations and principles of practice in musculoskeletal rehabilitation. Elsevier Health Sciences
18. Spiegelhalter DJ, Abrams KR, Myles JP (2004) Bayesian approaches to clinical trials and health-care evaluation. John Wiley & Sons
19. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936
20. RACGP (2010) Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men. The Royal Australian College of General Practitioners, South Melbourne
21. Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15
22. Jonsson B, Kanis J, Dawson A, Oden A, Johnell O (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193–199
23. Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C (2003) Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33:301–307
24. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47
25. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13
26. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236–242
27. Cheng T-T, Yu S-F, Hsu C-Y, Chen S-H, Su BY-J, Yang T-S (2013) Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines. Clin Ther 35:1005–1015
28. Zhang ZQ, Ho SC, Chen ZQ, Zhang CX, Chen YM (2014) Reference values of bone mineral density and prevalence of osteoporosis in Chinese adults. Osteoporos Int 25:497–507
29. Ministry of Health, P.R. China (2012) China public health statistical yearbook. Peking Union Medical College Publishing House, Beijing
30. Wang J, Wang Y, Liu WD, Wang F, Yin ZS (2014) Hip fractures in Hefei, China: the Hefei osteoporosis project. J Bone Miner Metab 32:206–214
31. Bow CH, Cheung E, Cheung CL et al (2012) Ethnic difference of clinical vertebral fracture risk. Osteoporos Int 23:879–885
32. Lofthus CM, Frihagen F, Meyer HE, Nordsletten L, Melhuus K, Falch JA (2008) Epidemiology of distal forearm fractures in Oslo, Norway. Osteoporos Int 19:781–786
33. Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES (1997) Fractures attributable to osteoporosis: report from the national osteoporosis foundation. J Bone Miner Res 12:16–23
34. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739
35. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fract Interv Trial Res Group Lancet 348:1535–1541
36. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077–2082
37. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818
38. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928
39. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521
40. Medicine price platform, Jiangsu Province. Bureau of Commodity Prices, Jiangsu Province. http://yy.jspn.net/ Accessed 4th July 2014
41. Qu B, Ma Y, Yan M, Wu HH, Fan L, Liao DF, Pan XM, Hong Z (2014) The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int 25:1853–1860
42. Wu M (2011) Research on the development of nursing home care: demand and supply [in Chinese]. Shandong University, Jinan
43. Liu Y, Yu D, Xu Z (2004) Health survey of 300 nursing home residents [in Chinese]. Chin J Geriatr 23:51
44. CCEMG, EPPI (2013) CCEMG – EPPI-Centre cost converter. http://eppi.ioe.ac.uk/costconversion/default.aspx Accessed 24th April 2013
45. Sun S, Chen J, Johannesson M, Kind P, Xu L, Zhang Y, Burstrom K (2011) Population health status in china: EQ-5D results, by age, sex and socio-economic status, from the national health services survey 2008. Qual Life Res 20:309–320
46. Si L, Winzenberg TM, de Graaff B, Palmer AJ (2014) A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporosis international
47. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA (2004) Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 20(Suppl 1):S27–S40
48. Eddy DM, Schlessinger L (2003) Validation of the Archimedes diabetes model. Diabetes Care 26:3102–3110
49. Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687–696
50. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674
51. Kung AW, Lee KK, Ho AY, Tang G, Luk KD (2007) Ten-year risk of osteoporotic fractures in postmenopausal Chinese women according to clinical risk factors and BMD T-scores: a prospective study. J Bone Miner Res Off J Am Soc Bone Miner Res 22:1080–1087
52. Park C, Ha YC, Jang S, Jang S, Yoon HK, Lee YK (2011) The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab 29:744–751
53. WHO (2014) Life expectancy: life tables by country China. World Health Organization. http://apps.who.int/gho/data/view.main.60340?lang=en Accessed April 16th 2014
54. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD (2012) Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making 32:722–732
55. Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 12:159–166
56. Hiligsmann M, Rabenda V, Bruyère O, Reginster J-Y (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170–177
57. Schwenkglenks M, Lippuner K (2007) Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int 18:1481–1491
58. Mueller D, Gandjour A (2008) Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Appl Health Econ Health Policy 6:113–135
59. Nshimyumukiza L, Durand A, Gagnon M et al (2013) An economic evaluation: simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res 28:383–394
60. Pro T (2006) User’s manual,(2006). TreeAge Software. Inc
61. Weinstein MC (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24:1043–1053
62. Hagen G, Wisløff T, Falch J, Lofthus C, Frihagen F, Wensaas K-A, Granum L, Nevjar J, Kristiansen I (2011) Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway. Norwegian Knowledge Centre for the Health Services
63. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–1558
64. Christensen PM, Brixen K, Gyrd-Hansen D, Kristiansen IS (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 96:387–396
65. Lewiecki EM, Gordon CM, Baim S et al (2008) International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43:1115–1121
66. NOF (2010) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington
67. Yu EW, Finkelstein JS (2012) Bone density screening intervals for osteoporosis: one size does not fit all. JAMA 307:2591–2592
68. Gourlay ML, Preisser JS, Lui LY, Cauley JA, Ensrud KE (2012) BMD screening in older women: initial measurement and testing interval. J Bone Miner Res 27:743–746
69. Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui L-Y, Ransohoff DF, Cauley JA, Ensrud KE (2012) Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 366:225–233
70. Weinstein MC (1980) Estrogen use in postmenopausal women—costs, risks, and benefits. N Engl J Med 303:308–316
71. Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices–modeling studies. Value Health 6:9–17
72. FRAX (2014) WHO fracture risk assessment tool. WHO. http://www.shef.ac.uk/FRAX/tool.aspx?lang=chs Accessed 09/07 2014
73. Chen XF, Li XL, Zhang H, Liu GJ (2014) Were you identified to be at high fracture risk by FRAX(R) before your osteoporotic fracture occurred? Clin Rheumatol 33:693–698
74. Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197
75. Mount H (2007) Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 30:1638–1646
76. Palmer AJ, Clarke P, Gray A et al (2013) Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health 16:670–685
77. Brown JB, Palmer AJ, Bisgaard P, Chan W, Pedula K, Russell A (2000) The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Prac 50(Suppl 3):S57–S64